Deerfield Management Company, L.P. (Series C) Vera Therapeutics, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.35 Billion
- Q2 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 3,348,117 shares of VERA stock, worth $70.8 Million. This represents 1.81% of its overall portfolio holdings.
Number of Shares
3,348,117
Previous 1,050,000
218.87%
Holding current value
$70.8 Million
Previous $25.2 Million
212.76%
% of portfolio
1.81%
Previous 0.64%
Shares
5 transactions
Others Institutions Holding VERA
# of Institutions
199Shares Held
62.3MCall Options Held
1.51MPut Options Held
268K-
Avoro Capital Advisors LLC New York, NY6.3MShares$133 Million2.71% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.48MShares$94.7 Million0.01% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.43MShares$72.4 Million9.64% of portfolio
-
Black Rock Inc. New York, NY3.34MShares$70.6 Million0.0% of portfolio
-
Vestal Point Capital, LP New York, NY3.1MShares$65.5 Million3.85% of portfolio
About Vera Therapeutics, Inc.
- Ticker VERA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,042,300
- Market Cap $572M
- Description
- Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...